8-K: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma reports completion of enrollment in Phase 3 EFZO-FIT study for pulmonary sarcoidosis and anticipates topline data in Q3 2025.

Summary

• aTyr Pharma announced its fourth quarter and full year 2024 financial results and provided a corporate update on March 13, 2025.
• Enrollment is complete in the Phase 3 EFZO-FIT study evaluating efzofitimod in pulmonary sarcoidosis, with topline data expected in the third quarter of 2025.
• The Phase 3 EFZO-FIT study enrolled 268 patients across 85 centers in nine countries.
• The company held a Type C meeting with the FDA to discuss the statistical analysis plan for the Phase 3 EFZO-FIT study.
• The fourth positive DSMB review for the Phase 3 EFZO-FIT study recommended the study continue without modifications.
• Enrollment is ongoing in the Phase 2 EFZO-CONNECT study evaluating efzofitimod in patients with systemic sclerosis-related interstitial lung disease, with interim data expected in the second quarter of 2025.
• A manuscript demonstrating the immunomodulatory activity of efzofitimod was published in Science Translational Medicine.
• The company presented preclinical research demonstrating anti-fibrotic effects of ATYR0101 in lung and kidney fibrosis.
• Eric Benevich was appointed to the company's Board of Directors.
• Cash, cash equivalents, restricted cash and available-for-sale investments totaled $75.1 million as of December 31, 2024.
• The company raised approximately $18.8 million in gross proceeds from its at-the-market (ATM) offering subsequent to the end of the fourth quarter 2024.
• The company believes its cash runway will be sufficient to fund operations for one year following the Phase 3 EFZO-FIT readout.
• Research and development expenses were $54.4 million for the year ended 2024.
• General and administrative expenses were $13.8 million for the year ended 2024.
• Collaboration and license revenue related to the Kyorin Agreement was $0.2 million for the year ended 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of enrollment in a Phase 3 trial, a positive DSMB review, and a publication validating the drug's mechanism of action; however, the company is still loss-making and dependent on future clinical trial results.

Positives

• Completion of enrollment in the Phase 3 EFZO-FIT study is a significant milestone.
• The fourth positive DSMB review for the Phase 3 EFZO-FIT study indicates a favorable safety profile for efzofitimod.
• Publication in Science Translational Medicine validates efzofitimod's mechanism of action.
• The company's cash position of $75.1 million, supplemented by $18.8 million from an ATM offering, provides a runway for upcoming milestones.
• FDA feedback on the statistical analysis plan for the Phase 3 EFZO-FIT study helps to finalize the assessment of study endpoints.

Negatives

• The company reported a net loss attributable to aTyr Pharma, Inc. of $64.023 million for the year ended December 31, 2024, compared to a net loss of $50.389 million for the year ended December 31, 2023.
• Cash, cash equivalents, restricted cash and available-for-sale investments decreased from $101.650 million at the end of 2023 to $75.076 million at the end of 2024.

Risks

• The success of the Phase 3 EFZO-FIT study is critical, and topline data in Q3 2025 will be a key event.
• The Phase 2 EFZO-CONNECT study is still ongoing, and interim data in Q2 2025 will be important for assessing the drug's efficacy in systemic sclerosis-related interstitial lung disease.
• The company's financial guidance depends on the Phase 3 EFZO-FIT readout and potential BLA filing, which are subject to regulatory risks.
• The company's cash runway is projected to last for one year following the Phase 3 EFZO-FIT readout, which means they will likely need to raise additional capital in the future.

Future Outlook

The company anticipates topline data from the Phase 3 EFZO-FIT study in the third quarter of 2025 and interim data from the Phase 2 EFZO-CONNECT study in the second quarter of 2025; the company believes its cash runway will be sufficient to fund operations for one year following the Phase 3 EFZO-FIT readout, which includes the potential filing of a Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis.

Management Comments

• Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr, stated that 2024 was an important year as they completed enrollment in the Phase 3 EFZO-FIT study.
• He also mentioned that the stage is set for 2025 to be a potential milestone year as they look toward reporting topline data for EFZO-FIT in the third quarter.
• Management is pleased with the execution of the study to date and the continued favorable safety profile demonstrated for efzofitimod.

Industry Context

aTyr Pharma is focused on developing treatments for interstitial lung disease (ILD), a market with limited therapeutic options and a need for safer and more effective treatments; the company's lead candidate, efzofitimod, targets pulmonary sarcoidosis and systemic sclerosis-related ILD, both of which represent significant unmet medical needs.

Comparison to Industry Standards

• The Phase 3 EFZO-FIT study is described as the largest interventional study ever conducted in pulmonary sarcoidosis, suggesting a significant commitment compared to other trials in this indication.
• Competitors in the ILD space include companies developing therapies targeting similar pathways or indications, such as Boehringer Ingelheim with Ofev (nintedanib) and Roche with Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF).
• aTyr's approach with efzofitimod, a tRNA synthetase derived therapy, represents a novel mechanism of action compared to some existing treatments.

Management Changes

Stakeholder Impact

• Positive results from the Phase 3 EFZO-FIT study could benefit patients with pulmonary sarcoidosis by providing a new treatment option.
• Positive results from the Phase 2 EFZO-CONNECT study could benefit patients with systemic sclerosis-related interstitial lung disease.
• The company's financial performance and cash runway are important for investors.
• The company's research and development activities could lead to new therapies for fibrosis and inflammation.

Next Steps

• Report topline data from the Phase 3 EFZO-FIT study in the third quarter of 2025.
• Report interim data from the Phase 2 EFZO-CONNECT study in the second quarter of 2025.
• Potentially file a Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis.
• Present posters at the American Thoracic Society (ATS) 2025 International Conference.

Key Dates